Progress of non-small-cell lung cancer with ROS1 rearrangement

Xin Yang; Zhe Tang; Jing Li; Jizong Jiang; Yue Liu

doi:10.3389/fmolb.2023.1238093

Frontiers in Molecular Biosciences (Dec 2023)

Progress of non-small-cell lung cancer with ROS1 rearrangement

Xin Yang,
Zhe Tang,
Jing Li,
Jizong Jiang,
Yue Liu

Affiliations

Xin Yang: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Zhe Tang: Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Jing Li: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Jizong Jiang: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Yue Liu: Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

DOI: https://doi.org/10.3389/fmolb.2023.1238093
Journal volume & issue: Vol. 10

Abstract

Read online

ROS1 rearrangement is found in 0.9%–2.6% of people with non-small-cell lung cancers (NSCLCs). Tyrosine kinase inhibitors (TKIs) target ROS1 and can block tumor growth and provide clinical benefits to patients. This review summarizes the current knowledge on ROS1 rearrangements in NSCLCs, including the mechanisms of ROS1 oncogenicity, epidemiology of ROS1-positive tumors, methods for detecting rearrangements, molecular characteristics, therapeutic agents, and mechanisms of drug resistance.

Published in Frontiers in Molecular Biosciences

ISSN: 2296-889X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Science: Biology (General)
Website: https://www.frontiersin.org/journals/molecular-biosciences

About the journal

Abstract

Keywords